Tharimmune, Inc. (NASDAQ: THAR), a publicly traded biotechnology company developing a new digital asset treasury strategy, announced the completion of a $545 million private placement. The funds will support the company’s plan to acquire Canton Coin (CC) and expand its participation in the Canton Network, a blockchain infrastructure for institutional financial markets.
The financing round was led by DRW and Liberty City Ventures, with participation from ARK Invest, Kraken, Polychain Capital, SBI Group, Tradeweb Markets, and the Canton Foundation. Tharimmune becomes the first publicly listed company backed by the Canton Foundation.
The company plans to use the proceeds to acquire CC tokens, operate as a Super Validator, and support the growth of applications built on the Canton Network. A portion of the funds will also be used for working capital and general corporate purposes.
Mark Wendland, former Partner and Chief Operating Officer at DRW, has been appointed Chief Executive Officer to lead the digital asset treasury initiative. Mark Toomey, formerly of Liberty City Ventures, has joined as President. The current management team will continue to oversee the company’s biotechnology operations.
Image: Freepik
